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See Article, pages 75–82Acetaminophen (APAP) is a widely used medication which has
been associated with dose-dependent liver injury and is the lead-
ing cause of acute liver failure in the U.S. and most of Europe [1].
Because of its highly reproducible effects in rodents, it has served
as a model hepatotoxin for more than forty years. A great deal of
information about the mechanism of its toxic effect has been
gained over this period, although research continues on the
details of several aspects of the cell death and tissue injury pro-
cess. To summarize some of the generally accepted facts on the
mechanism of injury, the drug is mainly metabolized to non-toxic
sulfate and glucuronide conjugates but a lesser fraction is con-
verted to an electrophilic reactive metabolite, NAPQI, mainly
mediated by Cyp2e1. NAPQI is preferentially detoxiﬁed by GSH;
when the GSH in cytoplasm and mitochondria is depleted, the
NAPQI covalently binds to protein-thiols. The mitochondria are
the key locus of dysfunction and an oxidative stress is induced
which ultimately leads to MPT-mediated necrosis [2]. ER stress
induced by covalent binding in the ER may also contribute [3],
but is likely by the amplifying toxic effects on mitochondria.
The ultimate development of MPT, however, depends on the par-
ticipation of signal transduction pathways in which the initial
oxidative stress activates kinases leading to JNK activation.
Activated JNK binds to its target, SH3BP5 (Sab) on the cytoplas-
mic face of the mitochondria outer membrane. This leads to a
self-sustaining mechanism which further impairs mitochondria
function and ampliﬁes ROS production which has two conse-
quences: sustaining JNK activation and promoting MPT [4,5].
Knockdown of Sab or both JNK 1 and/or 2 prevents acetamino-
phen toxicity without affecting GSH depletion or covalent bind-
ing [4,6]. Therefore, one may view this as a form of regulated
necrosis.
In the current issue Kim et al. have explored the hepatoprotec-
tive properties of the commonly used drug, metformin, in the
mouse APAP model [7]. Indeed, metformin, pretreatment
30 min before APAP was markedly protective. Importantly an
effect of metformin on APAP metabolism was excluded. The pro-
tection was accompanied by inhibition of JNK activation as wellJournal of Hepatology 20
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Open access under CC BY-NC-ND license.as its upstream activator MKK4, but not MKK7. As previously
described [8], APAP caused a rapid decline in p-AMPK, which
could not be reversed by metformin, making it unlikely that met-
formin was protective through its known effect to activate AMPK.
The authors then looked for upstream modulators of MAPK acti-
vation which might account for metformin’s inhibition of JNK
activation, focusing their attention on Gadd45b, a stress response
gene, known to downregulate JNK [9]. Gadd45b expression was
rapidly induced by APAP and was greatly ampliﬁed by met-
formin. The enhanced Gadd45b expression was associated with
decreased JNK activation and toxicity. Although Gadd45b was
only examined at the mRNA level and no data were provided
on protein levels, strong support for a causal relationship
between Gadd45b and its protective properties was provided
by administering APAP to Gadd45b knockout (KO) mice which
revealed markedly enhanced toxicity. The effect was cell autono-
mous, i.e. hepatocytes from these KO mice were much more sus-
ceptible to APAP-induced JNK activation and to death. Most
importantly, Gadd45b KO abrogated the metformin protective
effect. Furthermore, metformin protected wild-type mice even
when given one hour after APAP, offering some promise as a ther-
apeutic approach. However, the doses of metformin required to
exert such an effect may not be achievable in humans (Fig. 1).
This very well executed study provides convincing evidence
that metformin protects against APAP toxicity upstream of
p-JNK in a Gadd45b dependent fashion. JNK activation in APAP
toxicity involves at least two MAP3 kinases with the early partic-
ipation of MLK3 [10] and the subsequent participation of ASK1
[11]. Mitochondrial ROS are believed to play an important role
in activation of these MAP3K, either by oxidizing cytoplasmic
tethers or activation of upstream signaling (e.g. GSK3b or Src)
[11,12]. Gadd45b induction appears to be a compensatory stress
response which dampens toxicity. Although it is conceivable that
it is acting to directly inhibit MKK4, as there is experimental sup-
port it binds and inhibits MKK7 in other contexts [13], other pos-
sibilities should be considered such as direct inhibitory effects on
the upstream signaling kinases or indirect effects somehow lim-
iting mitochondrial ROS production.
Metformin is a known AMPK activator and AMPK activation
promotes autophagy, a compensatory protective pathway which
removes damaged mitochondria. Enhanced autophagy/mi-
tophagy is known to decrease APAP toxicity [14]. Kim et al. were

















Fig. 1. Signal transduction in APAP toxicity. JNK plays a key role in APAP
toxicity through its interaction with mitochondrial Sab which promotes ROS
release, sustaining JNK activation and ROS production, ultimately leading to MPT-
induced necrosis. Gadd45b is induced by either APAP or metformin alone and to a
greater extent by both. p-Stat3 is a repressor of Gadd45b expression which is
activated by APAP and suppressed by metformin. The exact mechanism of
Gadd45b induction by APAP and/or metformin is at present uncertain. However,
Gadd45b KO abrogates the protective effect of metformin and enhances APAP-
induced JNK activation and toxicity.
EditorialAMPK by metformin. Nevertheless, they also excluded an effect of
metformin on autophagy to account for protection.
The possible mechanism of induction of Gadd45b was consid-
ered in the Supplementary data. A role for transcription factors,
CAR and NF-jB, was excluded. Another known transcriptional
regulator (repressor) of Gadd45b is Stat-3 which was activated
after APAP, while metformin blocked this activation, suggesting
that activated Stat-3 may repress Gadd45b. However, no direct
evidence for the role of Stat-3 in APAP toxicity is provided and
this will require more extensive exploration. Furthermore, under
basal conditions the authors show that metformin induces
Gadd45b without an effect on Stat-3. Therefore, metformin
induces Gadd45b before APAP, independent of Stat-3, although
an effect on Stat-3 after APAP may amplify the induction by ‘lift-
ing the break’ but does not fully explain induction. Moreover,
APAP itself leads to submaximal Gadd45b induction and it is
not clear if APAP and metformin induce Gadd45b by the same
or independent mechanisms, nor if their effects are simply addi-
tive or potentiated.
Metformin exerts its effects through AMPK dependent and
independent mechanisms at pharmacologic and super-
pharmacologic doses [15]. The latter appears to be accounted
for by electrophoretic accumulation of positively-charged drug
into the mitochondrial matrix where it modestly inhibits
Complex1 which then restrains hepatic gluconeogenesis and
increases accumulation of lactic acid [16,17]. Metformin has been
shown to inhibitMPT and this effect is likely dependent on inhibit-
ing Complex1 at the initiation of the electron transport chain [18].
Complex1 inhibition by metformin can inhibit ROS production
[19]. How this factors into the regulation of Gadd45b induction
before or after APAP administration is not certain.
A number of uncertainties and controversies remain to be
clariﬁed in the ﬁeld of APAP toxicity, including exactly how the
interaction of JNK and Sab exert effects on mitochondrial func-
tion, the contribution of ER stress, the role of mitochondrial ﬁs-
sion, the contribution of necroptosis, and the role of DAMP
release from necrotic cells in inducing secondary inﬂammation6 Journal of Hepatology 2and collateral damage. These issues are under investigation in
many laboratories. However, the current work is an important
reminder that injury promoting mechanisms of cell death simul-
taneously are countered by adaptive measures to dampen the
progression of injury, and further enhancement of these adaptive
responses (e.g. enhanced mitophagy or Gadd45b) offer promising
therapeutic targets.
In summary, the work of Kim et al. reveals a protective effect
of metformin against APAP toxicity by inducing Gadd45b and
downregulating JNK. Further work will be needed to determine
the precise locus of action of Gadd45b and the mechanism of
its induction by metformin and APAP.Financial support
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